Eisai Signs Agreement on Marketing Halaven in 8 Central and Eastern European Countries

Eisai announced on April 5 that its UK subsidiary has signed an agreement on the promotion and distribution of its breast cancer treatment Halaven (eribulin mesylate) in Central and Eastern Europe with PharmaSwiss S.A. of Switzerland, the largest pharmaceutical distributor...read more